

**Dear all,**

This presentation is to express our interest in joining your team, And we wish our skills and experience qualify us to be a member of your team.

### **Who is VISUAL**

VISUAL is a leading advertising and marketing agency, we have been providing innovative, relevant and effective full service design & consultancy for Marketing, Events, Advertising, for a wide range of Industries.

### **What VISUAL does**

At VISUAL our mission is to create and deliver the world' s most compelling commercial content across all mediums and screens, The three things we care about are "Design, Quality, Price"...

### **Our core competencies**

-> ADVERTISING    -> MARKETING    -> BRANDING    -> DESIGN    -> PRODUCTION

Floor Stands

# Our Portfolio

Floor Stands



Floor Stands





Floor Stands




Floor Stands





Floor Stands



Floor Stands





Floor Stands





Floor Stands




Floor Stands





Floor Stands





Floor Stands



Counter Stands



Counter Stands





Counter Stands



Counter Stands





Counter Stands





Counter Stands





Pillar







Posters and Rollups





Posters and Rollups



Posters and Rollups



















Posters and Rollups



Posters and Rollups





Posters and Rollups

**ARISTON**



ضمان ٥ سنوات  
٥ سنوات ضمان  
٥ سنوات ضمان

**سخان أريستون ١٠ لتر  
للحمامات والمطابخ**

**مياه  
ساخنة  
طوال  
اليوم**

**خدمة العملاء: 19453**

**PENTAIR**


**TAQA MISR**  
FROM NATURE FOR NATURE



**حلول مبتكرة لتدفئة  
حمامات السباحة  
باستخدام الغلايات  
الأمريكية بينت آير**



planika  
INTELLIGENT FIRE



مدفئة اللهب المنزلية  
خيارات متنوعة تناسب جميع الاحتياجات

MADE IN POLAND

TAQA MISR™  
FROM NATURE FOR NATURE

TAQA MISR FROM NATURE FOR NATURE طاقة مصر من حلول الطبيعة



حلول تسخين المياه والتدفئة المركزية


ARISTON SIRA INDUSTRIE planika INTELLIGENT FIRE

PENTAIR CARLO POLETTI UNIDELTA

VENMAN VULCAN™ AL-TECH Aluminium Technology

11 El Obour Bldgs., Salah Salem St. Cairo, Egypt  
+202 2261 4715 +2010 9699 9980 @TAQAMISR www.taqamISR.com

**Avivavasc**  
Amlodipine 5-10 mg / Valsartan 160 mg



When it comes to **Decision**

For Healthcare Professionals Only

**Avivavasc**  
Amlodipine 5-10 mg / Valsartan 160 mg

When it comes to **Decision**

**Valsartan** achieved significantly earlier and more pronounced antihypertensive activity than with olmesartan, as demonstrated by : 7


(1) Significantly lower 24-hour, daytime, and nighttime ABPM values after 2 weeks with valsartan (P<.01);

(2) Significantly lower percentage of abnormal BP readings with valsartan;

(3) Significantly higher trough-peak ratio and smoothness index with valsartan, suggesting a more prolonged and homogeneous antihypertensive effect;

(4) Lower 24-hour postdose clinic systolic and diastolic BP values versus olmesartan

Mean  $\pm$ SD decreases from baseline in 24-hour, daytime and nighttime systolic and diastolic blood pressure obtained on ambulatory blood pressure monitoring after 2 and 8 weeks of treatment with olmesartan and valsartan. Differences (and 95% confidence intervals) between treatments are shown below each pair of histograms.



**Objective:** to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension.


**Study Design:** This was a prospective, randomized, open-label, blinded (masked) endpoint (PROBE), parallel-arm study. Consecutive outpatients of both sexes aged 35 to 75 years with mild-to-moderate essential hypertension, defined as diastolic blood pressure (DBP)  $\geq$ 95 mm Hg and  $<$ 110 mm Hg at the end of an initial 2-week washout period, were eligible for inclusion.

**No.:** 114 patients (64 men, 50 women; aged 35–70 years) were randomly assigned to receive valsartan 160 mg or olmesartan 20 mg once daily for 8 weeks.

**Avivavasc 5/160**  
Essential HTN Patient Stage 1 uncontrolled on Monotherapy

Essential HTN Patient Stage 1 with Coronary Artery Disease or Chronic Kidney Disease

Essential HTN Patient Stage 2 ( $\geq$  160) as Initiative Therapy




7. Destro M. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther. 2005; Jan-Feb;22(3):33-43.

**HSO**  
QUALITY OF HEALTHCARE

Address: 16 Al Moshair Ahmed Ismail St.,  
Square 160, Sheraton - Cairo, Egypt,  
Tel: (+202) 226 785 96 - 97  
Fax: (+202) 226 785 96 - 97  
Website: www.hsoegypt.com





**Glimet**  
Glibenclamide 2.5 - 5 mg  
Metformin hydrochloride 400 - 800 mg

Art of Tailoring

10<sup>th</sup> ANNIVERSARY

For Healthcare Professionals Only



**Glimet**  
Glibenclamide 2.5 - 5 mg  
Metformin hydrochloride 400 - 800 mg

- Glimet ..... More effective than monotherapy in improving glycemic control.
- Glimet ..... Significantly reduces HbA1C more than DPP-4.
- Glimet ..... Unique concentration ensures Flexible dosing Regimen.
- Glimet ..... Tablet Technology Formulation ensures least hypoglycemic attacks & 24-hrs glycemic control

**Glimet 2.5 /400:**

- Diabetic patient Type 2 uncontrolled on Monotherapy for 3 - 6 months with HbA1C  $\geq$  1.5% above their glycemic target

**Glimet Forte:**

- Diabetic patient Type 2 uncontrolled on any previous therapy " High Conc. Of any Monotherapy or Small Conc. Of any Combination"
- Newly diagnosed Diabetic Patient with HbA1C  $\geq$  9%

Dose: 1 - 2 tablets daily

**HSO**  
QUALITY OF HEALTHCARE  
Address: 16 Al Moshir Ahmed Ismail St.,  
Square 1160, Sheraton - Cairo, Egypt,  
Tel: (+202) 226 785 96 - 97  
Fax: (+202) 226 785 96 - 97  
Website: www.hsoegypt.com

Art of Tailoring

